Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Genentech discloses safety concerns over Avastin

Nature Biotechnology volume 22, page 1198 (2004)Cite this article

Colon cancer drug increases risk of embolisms

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Cambridge, Massachusetts

    Mark Ratner

Authors
  1. Mark Ratner
    View author publications

    Search author on:PubMed Google Scholar

Related links

Related links

Related links in Nature Research

Signal transduction inhibitors – a work in progress

Related external links

Genentech

Avastin (bevacizumab)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ratner, M. Genentech discloses safety concerns over Avastin. Nat Biotechnol 22, 1198 (2004). https://doi.org/10.1038/nbt1004-1198

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt1004-1198

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing